Are Wall Street Analysts Bullish on HCA Healthcare Stock?

HCA Healthcare, Inc. (HCA), headquartered in Nashville, Tennessee, owns and operates hospitals and related healthcare entities. Valued at $94.6 billion by market cap, the company provides diagnosis, treatments, consultancy, nursing, surgeries, and other services, as well as medical education, a physician resource center, and training programs.

Shares of this healthcare service provider have underperformed the broader market over the past year. HCA has gained 7.3% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 13.3%. However, in 2025, HCA’s stock rose 34.7%, surpassing the SPX’s 8.3% rise on a YTD basis.

More News from Barchart

Should You Buy the Dip as Palantir Stock Falls for 7 Straight Days? George Soros Is Betting Big on Beaten-Down UnitedHealth Stock. Should You? 2 ‘Strong Buy’ Stocks Offering Fat Yields of Over 7.5% in August 2025 Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines.

Narrowing the focus, HCA’s outperformance is apparent compared to the iShares U.S. Healthcare Providers ETF (IHF). The exchange-traded fund has declined about 18.4% over the past year. Moreover, HCA’s double-digit gains on a YTD basis outshine the ETF’s 3.3% losses over the same time frame.www.barchart.com

On Jul. 25, HCA shares closed down more than 2% after reporting its Q2 results. Its revenue increased 6.4% year over year to $18.6 billion. The company’s adjusted EPS came in at $6.84, up 24.4% from the year-ago quarter.

For the current fiscal year, ending in December, analysts expect HCA’s EPS to grow 19.8% to $26.30 on a diluted basis. The company’s earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.

Among the 26 analysts covering HCA stock, the consensus is a “Moderate Buy.” That’s based on 13 “Strong Buy” ratings, two “Moderate Buys,” and 11 “Holds.” www.barchart.com

This configuration is less bullish than a month ago, with 14 analysts suggesting a “Strong Buy.”

On Aug. 4,Benjamin Rossi from JPMorgan Chase & Co. (JPM) maintained a “Hold” rating on HCA with a price target of $370.

While HCA currently trades above its mean price target of $401.14, the Street-high price target of $444 suggests a 9.8% upside potential.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

View Comments